216
Participants
Start Date
June 18, 2024
Primary Completion Date
June 18, 2026
Study Completion Date
June 18, 2028
GP
gemcitabine + cisplatin
Adebrelimab
a PD-L1 inhibitor
concurrent chemoradiotherapy (CCRT)
concurrent chemoradiotherapy (CCRT)
NOT_YET_RECRUITING
Foshan First People's Hospital, Foshan
NOT_YET_RECRUITING
Affiliated cancer hospital and institute of guangzhou medical university, Guangzhou
NOT_YET_RECRUITING
Sun Yat-Sen Memorial Hospital, Guangzhou
NOT_YET_RECRUITING
The affiliated panyu central hospital of guangzhou medical university, Guangzhou
NOT_YET_RECRUITING
ZhuJiang Hospital of Southern Medical University, Guangzhou
NOT_YET_RECRUITING
Liuzhou Workers Hospital, Liuzhou
NOT_YET_RECRUITING
Guangxi Medical University Affiliated Cancer Hospital, Nanning
NOT_YET_RECRUITING
Cancer hospital of Shantou university medical college, Shantou
NOT_YET_RECRUITING
Cancer hospital Chinese academy of medical sciences, Shenzhen center, Shenzhen
RECRUITING
The second people's hospital of Shenzhen, Shenzhen
NOT_YET_RECRUITING
The university of Hongkong - Shenzhen hospital, Shenzhen
NOT_YET_RECRUITING
Guangdong Medical School First Affiliated Hospital, Zhangjiang
Sun Yat-sen University
OTHER